Farma

Computum
08.08.2018 kl 08:15 6201

Her er Nornes foreløpige kommentar:
"Sales in line, but mixed geographically; larger restructuring expenses

Photocure (PHO) released its 2Q18 report this morning. Hexvix/Cysview sales of NOK 42.4m were largely in line with our NOK 42.1m estimate. Additionally, NOK 3.2m in other sales were recognized due to milestone from Bellus Medical for Allumera and IFRS 15 adjustments. Adj. EBITDA (ex. one-off costs and milestone revenues) came in at NOK -1.7m, which was much better than our
NOK -5.3m projection. Still, the company incurred NOK -13.1m in restructuring expenses in the closed quarter bringing the bottom line to NOK -17.0m vs
NOK -6.4m in our estimates."

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.